FDA again extends review of Pfizer's Prevnar 13

12/30/2009 | Wall Street Journal, The · Yahoo!

Pfizer announced that the FDA has not completed its review of Prevnar 13, a new version of its vaccine for pneumococcal disease in children. The agency had also rescheduled its approval decision on the product in August. A company official said Pfizer remains confident in its application for Prevnar 13 despite the delays.

View Full Article in:

Wall Street Journal, The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA